SK Biopharm and Seoul Bio Hub Select Two Startups in the CNS Sector
Novorex and Three Brooks Therapeutics Selected
One-Year Research Consulting on Clinical Design and Regulatory Strategies
Collaboration Center Opened Within Seoul Bio Hub
On April 3, SK Biopharm announced that it has selected two promising startups in the central nervous system (CNS) field and held a signing ceremony through an open innovation program launched in collaboration with the bio-medical startup platform Seoul Bio Hub.
(From the left) Hyunwoo Kim, Director of Seoul Biohub Center; Sungyoung Kim, CEO of Three Brooks Therapeutics; Haera Kang, Head of Advanced Industry Division at Seoul Metropolitan Government; Woosung Son, CEO of Novorex; Seongwan Hwang, Head of R&D Division at SK Biopharm. SK Biopharm
View original imageThis agreement marks the first concrete outcome of the open innovation partnership signed last November between SK Biopharm and Seoul Bio Hub, aimed at strengthening domestic pharmaceutical and biotech R&D capabilities. The selected companies are Novorex and Three Brooks Therapeutics.
Novorex is focused on developing LRRK2 inhibitors, which are major targets for Parkinson's disease, utilizing artificial intelligence (AI)-based structural analysis technology. SK Biopharm plans to combine Novorex's precision target binding capabilities with its own global clinical design expertise to support the development of next-generation precision therapeutics from the preclinical stage.
Three Brooks Therapeutics addresses the root causes of neurodegenerative diseases such as Alzheimer's by removing intracellular waste through an autophagy activation mechanism. This aligns with SK Biopharm's strategic initiatives in neuro-immune and brain environment improvement sectors.
Over the next year, the selected companies will receive research consulting from SK Biopharm scientists, including proof-of-concept (PoC) support, R&D roadmap development for clinical entry, and strategies for global regulatory compliance. A collaboration center will be established within Seoul Bio Hub to serve as a practical base for cooperation with the selected companies, and the possibility of further partnerships with other promising startups will also be explored.
SK Biopharm has accumulated full-cycle new drug development experience through the independent development of cenobamate (marketed as Xcopri in the United States), an innovative treatment for epilepsy. Leveraging this expertise, the company plans to help domestic pharmaceutical and biotech startups meet global standards and further advance its collaborative framework with Seoul Bio Hub.
Hyunwoo Kim, Director of Seoul Bio Hub, stated, "This collaboration will be a significant step in strengthening the global new drug development capabilities and fostering the growth of promising biotech startups. We will continue to expand strategic partnerships with private companies to support the successful entry of domestic pharmaceutical and biotech firms into the global market."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Donghoon Lee, CEO of SK Biopharm, said, "This open innovation initiative is a strategic move to share SK Biopharm's global full-cycle new drug development playbook with innovative startups and create shared value. We aim to validate promising technologies in uncharted CNS areas such as neuro-immune at an early stage and build a globally competitive next-generation pipeline of innovative new drugs."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.